A detailed history of Wells Fargo & Company transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 1,144 shares of RPTX stock, worth $3,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,144
Previous 1,144 -0.0%
Holding current value
$3,248
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.02 - $4.7 $12 - $18
-4 Reduced 0.35%
1,144 $3,000
Q1 2024

May 10, 2024

SELL
$4.53 - $8.41 $144 - $269
-32 Reduced 2.71%
1,148 $5,000
Q4 2023

Feb 09, 2024

SELL
$3.22 - $11.79 $38 - $141
-12 Reduced 1.01%
1,180 $8,000
Q3 2023

Nov 13, 2023

SELL
$8.16 - $13.01 $155 - $247
-19 Reduced 1.57%
1,192 $14,000
Q2 2023

Aug 15, 2023

SELL
$8.63 - $12.53 $302 - $438
-35 Reduced 2.81%
1,211 $12,000
Q1 2023

May 12, 2023

SELL
$9.32 - $15.06 $16,729 - $27,032
-1,795 Reduced 59.03%
1,246 $12,000
Q4 2022

Feb 13, 2023

BUY
$12.5 - $18.13 $24,712 - $35,843
1,977 Added 185.81%
3,041 $44,000
Q3 2022

Nov 14, 2022

SELL
$11.57 - $15.59 $398,528 - $536,997
-34,445 Reduced 97.0%
1,064 $13,000
Q2 2022

Aug 12, 2022

BUY
$8.45 - $14.84 $297,566 - $522,590
35,215 Added 11977.89%
35,509 $497,000
Q1 2022

May 16, 2022

SELL
$11.38 - $21.88 $182 - $350
-16 Reduced 5.16%
294 $4,000
Q4 2021

Feb 14, 2022

SELL
$19.66 - $28.11 $6,094 - $8,714
-310 Reduced 50.0%
310 $7,000
Q3 2021

Nov 15, 2021

SELL
$25.71 - $35.24 $462 - $634
-18 Reduced 2.82%
620 $16,000
Q2 2021

Aug 16, 2021

SELL
$30.1 - $34.85 $26,488 - $30,668
-880 Reduced 57.97%
638 $20,000
Q1 2021

May 13, 2021

SELL
$25.89 - $44.46 $26,718 - $45,882
-1,032 Reduced 40.47%
1,518 $47,000
Q4 2020

Feb 09, 2021

BUY
$23.42 - $39.5 $59,721 - $100,725
2,550 New
2,550 $87,000

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $119M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.